The cure to cancer may not be hidden in some drug or chemical but within our own body. A team of Chinese researchers recently ...

A research team led by Professor Jeong Dong-jin of the Department of Radiology at the Catholic University of Korea's Yeouido St. Mary's Hospital (Professor Jeong Dae-young of Gastroenterology) has ...

The combination of epirubicin, cisplatin, and 5-fluorouracil (ECF) is widely used for gastric cancer treatment. However, cancer cells can acquire chemoresistance over multiple treatment cycles, ...

A postdevelopment study showed patients with gastric cancer were generally satisfied with the design and functionality of an intelligent individualized nutrition management applet.

Researchers at ASCO's annual meeting also discussed the importance of repeat biopsies to assess HER2 status after first-line ...

Gastric cancer is associated with a poor prognosis ... adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+ or in-situ hybridization (ISH)+) breast cancer who ...

“[T-DXd] is the first HER2-directed medicine to demonstrate an improvement in OS in a randomized phase 3 trial in the second-line metastatic setting of patients with HER2-positive gastric cancer, ...

Trastuzumab deruxtecan demonstrated a significant survival benefit in HER2-positive metastatic gastric cancer in the phase 3 DESTINY-Gastric04 ... as immunohistochemistry (IHC) 3+ or IHC 2+/in situ ...

Gastric cancer is associated with a poor prognosis ... adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+ or in-situ hybridization (ISH)+) breast cancer who ...

The participating centers were certified oncology centers according to the national audit program of the German Cancer Society ... construction and pull-up of a gastric conduit.

Breast carcinoma in situ incidence rates (European age-standardised (AS) rate) for persons are significantly higher than the UK average in England and Northern Ireland and significantly lower than the ...

“Pod Meets World,” that she is being treated for ductal carcinoma in situ. “It is very, very, very early,” said the “Boy Meets World” alumna, 43. “It’s technically Stage ...